A Promising New Treatment for Metastatic Triple-Negative Breast Cancer

Breast Cancer



Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Authors: Schmid, P. et. al.
Source: New England Journal of Medicine 

Triple negative breast cancer has poorer outcomes compared to other types of breast cancer. Researchers are trying to identify cellular targets to create effective therapies for this disease. One such target is a group of immune cells that can exist among the cancer cells. These cells have a receptor that, when activated, can turn off the immune cell and allow the cancer cells to grow. Researchers hypothesize that inhibiting that receptor activity can allow the immune cells to function and kill cancer cells. Atezolizumab is a chemotherapy agent that does just that. It is used in urologic and lung cancer cases. The investigators in this current study looked at the effectiveness of using atezolizumab with or without a taxane (a standard chemotherapy agent for triple- negative breast cancer) for cases of triple-negative breast cancer.


Read the full article: A Promising New Treatment for Metastatic Triple-Negative Breast Cancer

No comments have been posted

Leave a Comment